Durect company info

What does Durect do?
Durect (NASDAQ:DRRX) specializes in developing innovative drugs and therapies aimed at addressing acute and chronic health issues, focusing on areas such as pain management and other serious conditions. Traded on the NASDAQ stock exchange under the symbol DRRX, the company leverages its proprietary drug delivery technologies to improve the efficacy and safety profiles of existing and new pharmaceutical compounds. Durect's projects include advanced development programs for conditions that currently have limited treatment options, demonstrating its commitment to improving patient care and outcomes. The company's objectives center around advancing its research and development pipeline, securing partnerships to enhance market reach, and achieving regulatory approvals to bring transformative treatments to the healthcare market.
Durect  company media
Company Snapshot

Is Durect a public or private company?

key
Ownership
Public

How many people does Durect employ?

people
Employees
48

What sector is Durect in?

pie chart
Sector
Health Care

Where is the head office for Durect ?

location pin
Head Office
Cupertino, United States

What year was Durect founded?

founded flag
Year Founded
1998
What does Durect specialise in?
/Pharmaceutical Development /Drug Delivery Systems /Chronic Pain Management /Late Stage Development /Biodegradable Implants /Sustained Release Products

What are the products and/or services of Durect ?

Overview of Durect offerings
DUR-928: An endogenous, small molecule in Phase 2 development for the treatment of alcoholic hepatitis, NASH, and other liver diseases.
POSIMIR: A post-operative pain relief depot that delivers bupivacaine for up to 3 days after surgery.
ALZET Osmotic Pumps: Implantable pumps for continuous, controlled in vivo drug delivery for research use.
LACTEL Absorbable Polymers: Biodegradable polymers for controlled drug delivery, used in medical devices and pharmaceuticals.
SABER Technology: A patented drug delivery platform designed to release drugs at a controlled rate for a period of days to months.
ORADUR Technology: A technology that allows for the formulation of oral sustained release opioid products designed to discourage common methods of tampering.

Who is in the executive team of Durect ?

Durect leadership team
  • Dr. James E. Brown D.V.M.
    Dr. James E. Brown D.V.M.
    Co-Founder, CEO, President & Director
  • Mr. Timothy M. Papp M.B.A.
    Mr. Timothy M. Papp M.B.A.
    CFO & Secretary
  • Dr. Norman L. Sussman M.D.
    Dr. Norman L. Sussman M.D.
    Chief Medical Officer
  • Ms. Judy R. Joice
    Ms. Judy R. Joice
    Senior Vice President of Operations & Corporate Quality Assurance
  • Dr. WeiQi  Lin M.D., Ph.D.
    Dr. WeiQi Lin M.D., Ph.D.
    Executive VP of Research & Development and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Mr. Keith L. Lui M.B.A.
    Senior Vice President of Business Development, Commercial & Medical Affairs
  • Ms. Jian  Li M.B.A.
    Ms. Jian Li M.B.A.
    Senior VP of Finance, Corporate Controller & Secretary
  • Dr. Su Il Yum Ph.D.
    Dr. Su Il Yum Ph.D.
    Executive Officer